Shares of nano-cap stock Viveve Medical (NASDAQ:VIVE) have surged over 70% premarket on Tuesday after the company announced positive primary efficacy data from its Stress Urinary Incontinence study.
The study compared Viveve’s Cryogen-cooled Monopolar Radiofrequency (CMRF) treatment and a cryogen-only sham treatment to inert sham treatment for mild to moderate SUI in women.
Viveve’s share price…
Empfohlener Broker
Multi Asset Platform
The news saw Viveve’s share price surge as much as 75%. It is currently trading at $0.7824 per share, up by 47.62%—welcome news for a company whose stock price is down over 57% so far in 2020.
The company stated that it saw positive outcomes from its study…
“We are extraordinarily pleased to report positive results from our 3-arm SUI feasibility study,” said Scott Durbin, Viveve’s Chief Executive Officer.
The fact that we now have a true inert sham treatment tip provides us more confidence that our upcoming pivotal PURSUIT Trial can achieve its primary efficacy endpoint and position Viveve for a potential SUI indication in the United States.”